Dr. Clay Siegall has already made many strides in the field of biometrics to find the cures of various diseases through his start-up Seattle Genetics.As the world continues to develop, many incurable diseases crop up. Dr. Clay Siegall is on a mission to find the cure of some of these diseases through biotechnology.
This doctor began his journey in this field while he was studying zoology after his family member who had cancer become sicker after going through chemotherapy.
Although Dr. Clay Siegall has always been interested in medicine, the need to be his own boss and earn more also prompted him to want to own the patents to the medicine he was researching on.
Seattle Genetics has made numerous strides in the field of medicine and their first FDA approved drug is the first of its kind. The company first hit the profit path ten years ago and Dr. Siegall admits that before this there were some downhill days but his workaholic nature sailed him through it all. The company derives its revenue from patents, product partnerships and getting licenses for the processes of the drugs they have developed.
Seattle Genetics marketing strategy is mostly through referral and word of mouth. The company does seven figure deals and this takes patients and a lot of negotiations. The company’s legal team has helped them a lot in this end. Although the biometrics company has many unique products, Dr. Clay Siegall admits that hard work, being passionate and immense focus has gotten them to where they are today.
About Dr. Clay Siegall
Dr. Clay Siegall is an entrepreneur and a biometrics enthusiast. He started Seattle Genetics in 1998 and he is the current president, CEO and chairman of the organization. The company develops drug therapies for substantially severe diseases such as Cancer.
Prior to starting his own company, Dr.Siegall worked for Bristol-Myers which is a pharmaceutical company, the National Institutes of Health and the National Cancer Institute.
He is also one of the directors on the Alder Biopharmaceuticals Board of Directors.He also sits on the board of other pharmaceutical companies which include Ultragenyx and Mina Therapeutics among others. The biotechnology expert also holds more than ten patents and he has written more than 50 publications.